These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 25118480)

  • 1. Toxicity of concurrent chemoradiotherapy for locally advanced cervical cancer.
    Jakubowicz J; Blecharz P; Skotnicki P; Reinfuss M; Walasek T; Luczynska E
    Eur J Gynaecol Oncol; 2014; 35(4):393-9. PubMed ID: 25118480
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Feasibility and acute toxicity of Concurrent Chemoradiotherapy (CCRT) with high-dose rate intracavitary brachytherapy (HDR-ICBT) and 40-mg/m2 weekly cisplatin for Japanese patients with cervical cancer: results of a Multi-Institutional Phase 2 Study (JGOG1066).
    Toita T; Kitagawa R; Hamano T; Umayahara K; Hirashima Y; Aoki Y; Oguchi M; Mikami M; Takizawa K;
    Int J Gynecol Cancer; 2012 Oct; 22(8):1420-6. PubMed ID: 22932262
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of Treatment Time on Chemoradiotherapy in Locally Advanced Cervical Carcinoma.
    Pathy S; Kumar L; Pandey RM; Upadhyay A; Roy S; Dadhwal V; Madan R; Chander S
    Asian Pac J Cancer Prev; 2015; 16(12):5075-9. PubMed ID: 26163644
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Randomized Controlled Trial Comparing Clinical Outcomes and Toxicity of Lobaplatin- Versus Cisplatin-Based Concurrent Chemotherapy Plus Radiotherapy and High-Dose-Rate Brachytherapy for FIGO Stage II and III Cervical Cancer.
    Wang JQ; Wang T; Shi F; Yang YY; Su J; Chai YL; Liu Z
    Asian Pac J Cancer Prev; 2015; 16(14):5957-61. PubMed ID: 26320479
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical efficacy and toxicity of radio-chemotherapy and magnetic resonance imaging-guided brachytherapy for locally advanced cervical cancer patients: A mono-institutional experience.
    Lakosi F; de Cuypere M; Viet Nguyen P; Jansen N; Warlimont B; Gulyban A; Gennigens C; Seidel L; Delbecque K; Coucke P; Hermesse J; Kridelka F
    Acta Oncol; 2015; 54(9):1558-66. PubMed ID: 26406152
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase II study of concurrent chemo-radiotherapy with weekly nedaplatin in advanced squamous cell carcinoma of the uterine cervix.
    Yuan G; Wu L; Huang M; Li N; An J
    Radiat Oncol; 2014 Feb; 9():55. PubMed ID: 24533532
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase II study of bevacizumab in combination with definitive radiotherapy and cisplatin chemotherapy in untreated patients with locally advanced cervical carcinoma: preliminary results of RTOG 0417.
    Schefter TE; Winter K; Kwon JS; Stuhr K; Balaraj K; Yaremko BP; Small W; Gaffney DK
    Int J Radiat Oncol Biol Phys; 2012 Jul; 83(4):1179-84. PubMed ID: 22342094
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neoadjuvant chemotherapy followed by concurrent chemoradiation for locally advanced nasopharyngeal carcinoma.
    Kong L; Zhang YW; Hu CS; Guo Y
    Chin J Cancer; 2010 May; 29(5):551-5. PubMed ID: 20426907
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Feasibility study of toxicity outcomes using GEC-ESTRO contouring guidelines on CT based instead of MRI-based planning in locally advanced cervical cancer patients.
    Koh V; Choo BA; Lee KM; Tan TH; Low JH; Ng SY; Ilancheran A; Shen L; Tang J
    Brachytherapy; 2017; 16(1):126-132. PubMed ID: 27816539
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The prognostic factors for locally advanced cervical cancer patients treated by intensity-modulated radiation therapy with concurrent chemotherapy.
    Chen CC; Wang L; Lin JC; Jan JS
    J Formos Med Assoc; 2015 Mar; 114(3):231-7. PubMed ID: 25777974
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of Surgical Versus Clinical Staging in Chemoradiated FIGO Stage IIB-IVA Cervical Cancer Patients-Acute Toxicity and Treatment Quality of the Uterus-11 Multicenter Phase III Intergroup Trial of the German Radiation Oncology Group and the Gynecologic Cancer Group.
    Marnitz S; Martus P; Köhler C; Stromberger C; Asse E; Mallmann P; Schmidberger H; Affonso Júnior RJ; Nunes JS; Sehouli J; Budach V
    Int J Radiat Oncol Biol Phys; 2016 Feb; 94(2):243-53. PubMed ID: 26853333
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Extended-field radiotherapy and high-dose-rate brachytherapy with concurrent and adjuvant cisplatin-based chemotherapy for locally advanced cervical cancer: a phase I/II study.
    Chung YL; Jian JJ; Cheng SH; Hsieh CI; Tan TD; Chang HJ; Hung CF; Horng CF; Soong T; Tsou MH
    Gynecol Oncol; 2005 Apr; 97(1):126-35. PubMed ID: 15790448
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcome and toxicity of radical radiotherapy or concurrent Chemoradiotherapy for elderly cervical cancer women.
    Wang W; Hou X; Yan J; Shen J; Lian X; Sun S; Liu Z; Meng Q; Wang D; Zhao M; Qiu J; Hu K; Zhang F
    BMC Cancer; 2017 Aug; 17(1):510. PubMed ID: 28764676
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II study of concurrent chemoradiotherapy with high-dose-rate intracavitary brachytherapy in patients with locally advanced uterine cervical cancer: efficacy and toxicity of a low cumulative radiation dose schedule.
    Toita T; Kitagawa R; Hamano T; Umayahara K; Hirashima Y; Aoki Y; Oguchi M; Mikami M; Takizawa K;
    Gynecol Oncol; 2012 Aug; 126(2):211-6. PubMed ID: 22555110
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Concurrent definitive chemoradiation incorporating intensity-modulated radiotherapy followed by adjuvant chemotherapy in high risk locally advanced cervical squamous cancer: a phase II study.
    Zhang GY; Zhang R; Bai P; Li SM; Zhang YY; Chen YR; Huang MN; Wu LY
    BMC Cancer; 2022 Dec; 22(1):1331. PubMed ID: 36539745
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase I study of concurrent weekly topotecan and cisplatin chemotherapy with whole pelvic radiation therapy in locally advanced cervical cancer: a gynecologic oncology group study.
    Rose PG; Sill MW; McMeekin DS; Ahmed A; Salani R; Yamada SD; Wolfson AH; Fusco N; Fracasso PM
    Gynecol Oncol; 2012 Apr; 125(1):158-62. PubMed ID: 22198338
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multi-institutional phase II clinical study of concurrent chemoradiotherapy for locally advanced cervical cancer in East and Southeast Asia.
    Kato S; Ohno T; Thephamongkhol K; Chansilpa Y; Yuxing Y; Devi CR; Bustam AZ; Calaguas MJ; de los Reyes RH; Cho CK; Dung TA; Supriana N; Mizuno H; Nakano T; Tsujii H
    Int J Radiat Oncol Biol Phys; 2010 Jul; 77(3):751-7. PubMed ID: 19836154
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Efficacy of Palonosetron Plus Dexamethasone in Preventing Chemoradiotherapy-induced Nausea and Emesis in Patients Receiving Daily Low-dose Cisplatin-based Concurrent Chemoradiotherapy for Uterine Cervical Cancer: A Phase II Study.
    Mitsuhashi A; Usui H; Nishikimi K; Yamamoto N; Hanawa S; Tate S; Watanabe-Nemoto M; Uno T; Shozu M
    Am J Clin Oncol; 2017 Apr; 40(2):118-121. PubMed ID: 25144265
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Concurrent weekly cisplatin and radiotherapy in routine management of cervical cancer: a report on patient compliance and acute toxicity.
    Serkies K; Jassem J
    Int J Radiat Oncol Biol Phys; 2004 Nov; 60(3):814-21. PubMed ID: 15465198
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multi-institutional Observational Study of Prophylactic Extended-Field Concurrent Chemoradiation Therapy Using Weekly Cisplatin for Patients With Pelvic Node-Positive Cervical Cancer in East and Southeast Asia.
    Wakatsuki M; Kato S; Ohno T; Banu PA; Hoang NC; Yadamsuren E; Supriana N; Cao J; Devi CRB; Calaguas MJ; Chansilpa Y; Cho CK; Adylkhanov T; Okonogi N; Nakano T; Tsujii H
    Int J Radiat Oncol Biol Phys; 2019 Sep; 105(1):183-189. PubMed ID: 31125594
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.